Bayer AG (XSWX:BAYN) Accounts Payable: CHF5,993 Mil (As of Mar. 2026)


XSWX:BAYN Bayer AG XSWX:BAYN
48 GF Score
Price CHF42.49
GF Value CHF24.74
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Bayer AG Accounts Payable?

Bayer AG XSWX:BAYN 48 Accounts Payable is CHF5,993 Mil as of Mar. 2026. GuruFocus rates XSWX:BAYN with a GF Score™ of 48/100 and a GF Value™ of CHF24.74 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Bayer AG's Accounts Payable for the quarter that ended in Mar. 2026 was CHF5,993 Mil.

Bayer AG's quarterly Accounts Payable increased from Sep. 2025 (CHF5,962 Mil) to Dec. 2025 (CHF6,608 Mil) but then declined from Dec. 2025 (CHF6,608 Mil) to Mar. 2026 (CHF5,993 Mil).

Bayer AG's annual Accounts Payable declined from Dec. 2023 (CHF7,032 Mil) to Dec. 2024 (CHF7,019 Mil) and declined from Dec. 2024 (CHF7,019 Mil) to Dec. 2025 (CHF6,608 Mil).

Bayer AG Accounts Payable Historical Data

* Premium members only.

The historical data trend for Bayer AG's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bayer AG Accounts Payable Chart

Bayer AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7,068.29 7,445.89 7,031.57 7,018.90 6,607.55

Bayer AG Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6,292.19 5,663.32 5,962.34 6,607.55 5,993.49
XSWX:BAYN
48GF Score
Bayer AG XSWX:BAYN
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bayer AG Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of CHF5,993 Mil mean?
Bayer AG (XSWX:BAYN) has a Accounts Payable of CHF5,993 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Bayer AG and its competitors.
Is Bayer AG's Accounts Payable too high?
Bayer AG's current Accounts Payable is CHF5,993 Mil. Overall, Bayer AG has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bayer AG's Accounts Payable compare to LLY and JNJ?
Bayer AG's Accounts Payable of CHF5,993 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Drug Manufacturers company?
A good Accounts Payable depends on the Drug Manufacturers industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Bayer AG and its competitors. Bayer AG's current Accounts Payable is CHF5,993 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bayer AG stock overvalued right now?
Based on GuruFocus' analysis, Bayer AG (XSWX:BAYN) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF24.74, compared to a current price of CHF42.49 — trading 71.7% above its estimated fair value. The current Accounts Payable is CHF5,993 Mil. Bayer AG's overall GF Score™ is 48/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Bayer AG (XSWX:BAYN), the current Accounts Payable is CHF5,993 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bayer AG (XSWX:BAYN) Overvalued in 2026?

Based on GuruFocus' analysis, Bayer AG stock appears to be overvalued. The current stock price of CHF42.49 is trading 71.7% above its estimated GF Value™ of CHF24.74. GuruFocus considers Bayer AG to be Significantly Overvalued.

Key valuation signals for XSWX:BAYN:

  • Accounts Payable: CHF5,993 Mil
  • GF Value™: CHF24.74 vs. price of CHF42.49 (71.7% above fair value)
  • GF Score™: 48/100 with 6 warning signs

No single metric tells the full story. See the XSWX:BAYN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bayer AG Business Description

Address Kaiser-Wilhelm-Allee 1, Leverkusen, NW, DEU, 51368
Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs (about 38% of total sales in 2025) as well as vitamins and other consumer healthcare products (13% of total). The firm's crop science business (47% of total) sells seeds, pesticides, herbicides, and fungicides, which was expanded through its 2018 acquisition of Monsanto.
48GF Score

Get the complete analysis for XSWX:BAYN

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF42.49
Price
CHF24.74
GF Value